Pharsight

Precedex generic

Precedex is an injectable medication owned by Hospira. It contains dexmedetomidine hydrochloride as an active ingredient. Precedex was first authorised for market use on 17 December, 1999.

When will Precedex generic be available?

Precedex generic is expected to be available after 4 July, 2032. The drug holds a total of 13 patents, none of which have expired so far. The last patent is scheduled to expire on 4 July, 2032.

Precedex uses

Precedex is primarily used for sedation. dexmedetomidine hydrochloride, the active ingredient, contributes to its effectiveness by slowing down brain activity which results in a relaxed and calm state.

Precedex patent expiration

Precedex holds 13 patents with none expired. These patents mainly cover dexmedetomidine premix formulation and methods of treatment using it. The last patent, titled 'Dexmedetomidine premix formulation', is set to expire on 4th July 2032. Below is the details of the patent:

EPO Oppostions filed on Precedex

Litigations filed on Precedex

Precedex dosage

Want to ask something?